Connect with us



Google backs pharma startup

Google has invested in a US-China pharmaceutical tech startup.

XtalPi, which pioneers Intelligent Digital Drug Discovery and Development (ID4), harnesses ‘artificial intelligence, quantum physics, and high-performance cloud computing’ to improve the efficiency of drug production.

And it has raised $15 million in a Series B funding round, which concluded this week – and was led by Sequoia China, along with Google and Tencent.

“XtalPi’s AI platform is a powerful new tool for drug development that has already been adopted by key researchers. Their technologies, such as ID4, could help to propel pharmaceutical R&D productivity and capabilities while reducing costs. We’re pleased to be supporting this strong team, and we’re excited to see where they go from here,” said Frank Lin, Principal, Corporate Development – North Asia, Google.

A new research lab will be one of the new developments supported by the $15 million investment.

“At XtalPi, we believe that algorithmic power is the key to finding smarter, more effective routes for drug research and development, and we are focused on building a computational engine that empowers and expedites pharmaceutical innovation for companies worldwide,” added XtalPi Co-founder and Chairman of the Board Dr Shuhao Frank Wen.

Newsletter Signup

Written By


New €7M fund launches to support data-driven climate solutions in Europe

Editor's Picks

How smart cities cut emissions

Top 2021 stories

cities cities

Smart cities slash emissions

Editor's Picks

Google and Orange make startup pact


Newsletter Signup